Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort

Antiviral Therapy

Volumn 12, Issue 5, 2007, Pages 753-760

  Boulle, Andrew ^a   Orrell, Catherine ^b   Kaplan, Richard ^c   Van Cutsem, Gilles ^d   McNally, Matthew ^c   Hilderbrand, Katherine ^a,d   Myer, London ^a   Egger, Matthias ^e   Coetzee, David ^a,c   Maartens, Gary ^a   Wood, Robin ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL COUNT; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERSENSITIVITY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SOUTH AFRICA;

ACIDOSIS, LACTIC; ADULT; ANTI-HIV AGENTS; BODY WEIGHT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICIAN'S PRACTICE PATTERNS; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547814064     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Geneva: World Health Organization.
2. National Department of Health (2004) Antiretroviral Treatment Guidelines, 1st edn. Pretoria: National Department of Health.
3. Nolan D, Mallal S. Thymidine analogue-sparing highly active antiretroviral therapy (HAART). J HIV Ther 2003; 8:2-6.
4. Lonergan JT, McComsey GA, Fisher RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2004; 36:935-942.
5. Dragovic G, Jevtovic D. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother 2003; 14:281-284.
6. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
7. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96:722-724.
8. Carr A. Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet 2002; 360:81-85.
9. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 2006; 96:315-320.
10. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
11. National Department of Health (2006) Antenatal HIV and Syphilis Prevalence Survey 2005. Pretoria: National Department of Health.
12. Provincial Government of the Western Cape. Antiretroviral Treatment Protocol. Version 2; 2004. Cape Town: Provincial Government of the Western Cape.
13. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
14. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776.
15. Orrell C, Harling G, Lawn S, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88.
16. Coetzee D, Boulle A, Hildebrand K, Asselman V, Van CG, Goemaere E. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004; 18 Suppl 3:S27-S31.
17. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance are for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1-19.
18. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91:1229-1235.
19. Mandalia S, Parmar D, Fisher M, et al. Naively changing HAART. HIV Med 2002; 3:254-262.
20. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. Br Med J 2005; 330:695.
21. d'Arminio MA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507.
22. Kirstein LM, Greenblatt RM, Anastos K, et al. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2002; 29:495-503.
23. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185-194.
24. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829.
25. Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 2005; 24:5-15.
26. Meta-analysis of efficacy and safety for clinical studies of d4T 40mg versus 30mg BID in 1008 patients. XVI International AIDS Conference. 13-18 August 2006, Toronto, Canada. Abstract ThPE0120.
27. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137-151.
28. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51:524-532.